ESPAÑOL ENGLISH

Rodríguez Abreu, Delvys

Publicaciones

All

Articles

Conference Papers

Annotation

Lecture

Others

Type

30 artículo
6 actas de congresos

By researcher

By affiliation

1
2

Title Issue Date
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study Boyer, Michael; Şendur, Mehmet A.N.; Rodríguez Abreu, Delvys ; Park, Keunchil; Lee, Dae Ho, et al Issued date: 2021 DOI: 10.1200/JCO.20.03579 Source: Journal of Clinical Oncology [ISSN 0732-183X], v. 39(21), p. 2327-2338 (Enero 2021) SJR: 9,378 - Q1 JCR: 50,717 - Q1 SCIE MIAR ICDS: 11,0 Artículo
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021,-189, and-407 Powell, Steven F.; Rodríguez Abreu, Delvys ; Langer, Corey J.; Tafreshi, Ali; Paz-Ares, Luis, et al Issued date: 2021 DOI: 10.1016/j.jtho.2021.06.020 Source: Journal of Thoracic Oncology [ISSN 1556-0864], v. 16 (11), p. 1883-1892 (Noviembre 2021) SJR: 4,744 - Q1 JCR: 20,121 - Q1 SCIE MIAR ICDS: 10,7 Artículo
Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review Cobo, M; Rodriguez Abreu, Delvys ; Parente, DP; Gracia, PR; Gonzalez, JG Issued date: 2021 DOI: 10.1007/s40487-021-00139-3 Source: Oncology And Therapy [ISSN 2366-1070], v. 9(1), p. 41-53 (Junio 2021) SJR: 0,125 - Q4 ESCI MIAR ICDS: 9,2 Artículo
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 Rodríguez Abreu, Delvys ; Powell, S. F.; Hochmair, M. J.; Gadgeel, S.; Esteban, E., et al Issued date: 2021 DOI: 10.1016/j.annonc.2021.04.008 Source: Annals Of Oncology[ISSN 0923-7534],v. 32 (7), p. 881-895, (Julio 2021) SJR: 8,59 - Q1 JCR: 51,769 - Q1 SCIE MIAR ICDS: 11,0 Artículo
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial Jotte, Robert; Cappuzzo, Federico; Vynnychenko, Ihor; Stroyakovskiy, Daniil; Rodríguez Abreu, Delvys , et al Issued date: 2020 DOI: 10.1016/j.jtho.2020.03.028 Source: Journal of Thoracic Oncology [ISSN 1556-0864] , v. 15(8), p. 1351-1360 SJR: 4,539 - Q1 JCR: 15,609 - Q1 SCIE Artículo
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial Peters, Solange; Danson, Sarah; Hasan, Baktiar; Dafni, Urania; Reinmuth, Niels, et al Issued date: 2020 DOI: 10.1016/j.jtho.2020.06.011 Source: Journal of Thoracic Oncology [ISSN 1556-0864], v. 15(10), p. 1647-1656 SJR: 4,539 - Q1 JCR: 15,609 - Q1 SCIE Artículo
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study Rudin, Charles M.; Awad, Mark M.; Navarro, Alejandro; Gottfried, Maya; Peters, Solange, et al Issued date: 2020 DOI: 10.1200/JCO.20.00793 Source: Journal of Clinical Oncology [EISSN 1527-7755], v. 38 (21), p. 2369-2379, (Julio 2020) SJR: 10,482 - Q1 JCR: 44,544 - Q1 SCIE Artículo
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer Gadgeel, S; Rodríguez Abreu, Delvys ; Speranza, G; Esteban, E; Felip, E, et al Issued date: 2020 DOI: 10.1200/JCO.19.03136 Source: Journal of Clinical Oncology [ISSN 0732-183X], v. 38(14), p. 1505-1517 SJR: 10,482 - Q1 JCR: 44,544 - Q1 SCIE Artículo
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Garassino, Marina C.; Gadgeel, Shirish; Esteban, Emilio; Felip, Enriqueta; Speranza, Giovanna, et al Issued date: 2020 DOI: 10.1016/S1470-2045(19)30801-0 Source: Lancet Oncology[ISSN 1470-2045],v. 21 (3), p. 387-397, (Marzo 2020) SJR: 13,53 - Q1 JCR: 41,316 - Q1 SCIE Artículo
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials Borghaei, Hossein; Langer, Corey J.; Paz-Ares, Luis; Rodríguez-Abreu, Delvys ; Halmos, Balazs, et al Issued date: 2020 DOI: 10.1002/cncr.33142 Source: Cancer [ISSN 0008-543X], v. 126(2), p. 4867-4877 SJR: 3,052 - Q1 JCR: 6,86 - Q1 SCIE Artículo
Modulation of oxidative stress by ozone therapy in the prevention and treatment of chemotherapy-induced toxicity: Review and prospects Clavo Varas, Bernardino ; Rodríguez Esparragón, Francisco Javier ; Rodríguez Abreu, Delvys ; Martínez Sánchez, Gregorio; Llontop, Pedro, et al Issued date: 2019 DOI: 10.3390/antiox8120588 Source: Antioxidants, [ISSN 2076-3921], v. 8 (12), (Diciembre 2019) SJR: 1,1 - Q1 JCR: 5,014 - Q1 SCIE Artículo
IMpower131: Final OS Results of Carboplatin plus Nab-Paclitaxel +/- Atezolizumab in Advanced Squamous NSCLC Jotte, R.; Cappuzzo, F.; Vynnychenko, I.; Stroyakovskiy, D.; Rodríguez Abreu, Delvys , et al Issued date: 2019 DOI: 10.1016/j.jtho.2019.08.484 Source: Journal of Thoracic Oncology [ISSN 1556-0864], v. 14 (10) (sup. S), p. S243-S244, (Octubre 2019) SJR: 3,218 - Q1 JCR: 13,357 - Q1 SCIE Actas de congresos
KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC Gadgeel, S.; Rodríguez Abreu, Delvys ; Felip, E.; Esteban, E.; Speranza, G., et al Issued date: 2019 Source: Annals Of Oncology [ISSN 0923-7534], v. 30 sup. 11, p. 64-65, Abstract LBA5, (Diciembre 2019) SJR: 1,039 - Q1 JCR: 18,274 - Q1 SCIE Actas de congresos
IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations Curioni-Fontecedro, Alessandra; Mok, Tony; Socinski, Mark A.; Reck, Martin; Jotte, Robert M., et al Issued date: 2019 Source: Swiss Medical Weekly [ISSN 1424-7860], v. 149 (sup. 237), p. 14S, Abstract 1072, (Junio 2019) SJR: 0,532 - Q2 JCR: 1,822 - Q2 SCIE Actas de congresos
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer Gandhi, Leena; Rodríguez Abreu, Delvys ; Gadgeel, Shirish M.; Esteban, Emilio; Felip, Enriqueta, et al Issued date: 2018 DOI: 10.1056/NEJMoa1801005 Source: New England Journal Of Medicine [ISSN 0028-4793], v. 378 (22), p. 2078-2092, (Mayo 2018) SJR: 19,524 - Q1 JCR: 70,67 - Q1 SCIE Artículo
IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations Mok, T. S. K.; Socinski, M. A.; Reck, M.; Jotte, R. M.; Lim, D. W-T., et al Issued date: 2018 DOI: 10.1093/annonc/mdy483.008 Source: Annals Of Oncology [ISSN 0923-7534], v. 29 sup. 9, Abstract LBA9, (Noviembre 2018) p. ix177-ix178 SJR: 6,047 - Q1 JCR: 14,196 - Q1 SCIE Actas de congresos

1
2